Louis F. Centofanti
Analyst · Wedbush Securities
Thank you, David, and welcome, everyone. Although we have continued to face a very challenging fiscal environment, we achieved our second consecutive quarter of positive EBITDA. As always, our business remains lumpy due to timing, and as it happened in this quarter, we received several meaningful shipments late in the quarter. Had it not been for the timing of these shipments, our EBITDA would have been even stronger. Our Treatment backlog increased from $5.9 million to $8.9 million. Overall, we anticipate a gradual improvement in funding for DOE treatment projects. As I stated in the past, there is really significant pent-up demand due to the various shutdowns and delay treatment at a number of the DOE sites. Notwithstanding the temporary government shutdown October, which compounded our short-term issues, we remain optimistic on the waste side. Within the Service segment, as we've previously disclosed, our Plateau contract expired on September 30, which will have a meaningful impact on revenue going forward. We planned for this and have adjusted our expenses accordingly. CH2M Hill remains one of our largest and most supportive customers, and we will continue to pursue opportunities as strategic partners. Despite these setbacks, we believe the funding environment is also starting to improve within the Service segment. Again, the government shutdown certainly didn't help, but we continue to receive small contracts, and we're actively bidding on a number of fairly sizable projects. Service pipeline is significant, and it's now just a matter of waiting for the projects to be awarded. Turning back to the Treatment segment. We see a number of exciting opportunities treating more complex, higher active waste streams. We have continued to focus on the Hanford tank waste. Still too early to know the timing, but from where we sit today, we offer DOE the best option for early treatment of some of the tank waste at Hanford. I think, as you all know, remember, none of that tank waste has ever been treated since the days of its production early in the Manhattan project, demonstrating our capabilities to treat tank waste at Hanford. Even on a small scale, it would open the door to much larger opportunities. As I have explained in the past, our permits and licenses at our Northwest facility allow us to accept these waste streams for treatment today. We are the only commercial treatment facility in the U.S. that can handle these high-priority Hanford waste streams. Outside of DOE, we've increased our sales and marketing efforts, in particular, on the international front and working aggressively on a number of opportunities in North America and Europe. Now turning to the medical isotope project. We continue to focus on our R&D efforts on advancing our technology. As I've discussed in the past, the current supply chain for this isotope tech-99 is very fragile, which is best illustrated by the recent shutdown in the last several months of 2 of the major reactors that produce tech-99. The good and bad of the situation is that it highlights the need for our process. The flip side is that it's -- several of these backup reactors are now being used to produce tech-99, which has hampered our ability to secure reactor time to run our next series of high-level tests to prove our process. We're addressing these issues and look forward to moving forward in the very near future. Finally, I'm pleased to welcome John Climaco to our Board of Directors. John brings expensive legal, operational experience, including strategic planning and business development. He will be heading a new committee, active -- to actively review strategic options for all of the aspects of the business. He brings direct experience in the medical nuclear industry, which will be especially helpful as we move forward on some of these upcoming initiatives. So to wrap up, even in a bleak market, we generated positive EBITDA 2 quarters in a row. Our backlog has increased. We expect funding environment will begin to improve in the new year. And probably, more importantly, as a result of our major cost-saving initiatives, any incremental growth and revenue should translate to very meaningful improvements in our bottom line. At the same time, we're working on a number of important initiatives, including our proposal to treat tank waste, and we're also bidding on a large number of service contracts and are aggressively working to expand our international and commercial business. We remain optimistic about the outlook and look forward to providing further details as the developments unfold. At this point, I'd like to call -- turn the call over to Ben, who will go into more detail on the numbers, and I'll get back to answer questions. Thank you.